DALILA DARMOUL

Dr. DALILA DARMOUL

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
VGValérie Gratio
Valérie Gratio
NBNathalie Beaufort
Nathalie Beaufort
LSLina Seiz
Lina Seiz
JMJosefine Maier
Josefine Maier
GVG. Duke Virca
G. Duke Virca
DDDALILA DARMOUL
DALILA DARMOUL

27 January 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
VGValérie Gratio
Valérie Gratio
FWFrancine Walker
Francine Walker
TLThérèse Lehy
Thérèse Lehy
MLMarc Laburthe
Marc Laburthe
DDDALILA DARMOUL
DALILA DARMOUL
Thrombin is now recognized as an important factor in many cancers. Here, we examined the expression and role of the recently discovered thrombin receptor PAR4, in human colon cancer cells. PAR4 mRNA was found in 10 out of 14 (71%) human colon cancer cell lines tested but not in epithelial cells isolated from normal human colon. This finding is in line with immunostaining results of PAR4 in human colon tumors and its absence in normal human colonic mucosa. Investigation of the functional significance of the aberrant expression of PAR4 in colon cancer cells revealed (i) a prompt increase in intracellular calcium concentration on challenge with PAR4‐specific agonist AP4 (100 μM) and (ii) marked mitogenic response (2.5‐fold increase in cell number) in a dose‐dependent manner on treatment with AP4 (0.1–300 μM). Analysis of the signaling pathways downstream of PAR4 activation in HT29 cells showed (i) a sustained phosphorylation of extracellular signal‐related kinase 1/2 (ERK1/2) and (ii) the involvement of epidermal growth factor receptor B‐2 (ErbB‐2) but not of epidermal growth factor receptor in PAR4‐induced mitogen‐activated protein kinase activation. Tyrphostin AG1478, the ErbB inhibitor, reversed the action of AP4 on ERK1/2 and ErbB‐2 phosphorylation and HT29 cell growth. Finally, the Src inhibitor PP2 abrogated ErbB‐2 and ERK phosphorylation and HT29 cell proliferation, suggesting the essential role of Src activity in PAR4‐induced phosphorylation of ErbB‐2. These data highlight the role of PAR4 as a new important player in the control of colon tumors and underline the critical role of ErbB‐2 transactivation.

1 November 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
VGValérie Gratio
Valérie Gratio
CLCéline Loriot
Céline Loriot
GVG. Duke Virca
G. Duke Virca
KOKaterina Oikonomopoulou
Katerina Oikonomopoulou
FWFrancine Walker
Francine Walker
DDDALILA DARMOUL
DALILA DARMOUL

18 April 2014 in Biological Chemistry
Verified
Journal Article
Closed access
FWFrancine Walker
Francine Walker
PNPascal Nicole
Pascal Nicole
AJAbdelhak Jallane
Abdelhak Jallane
ASAntoninus Soosaipillai
Antoninus Soosaipillai
VMValentine Mosbach
Valentine Mosbach
DDDALILA DARMOUL
DALILA DARMOUL
Emerging evidence indicates that serine proteases of the tissue kallikrein-related peptidases family (KLK) are implicated in tumorigenesis. We recently reported the ectopic expression of KLK4 and KLK14 in colonic cancers and their signaling to control cell proliferation. Human tissue kallikrein-related peptidase 7 (KLK7) is often dysregulated in many cancers; however, its role in colon tumorigenesis has not yet been established. In the present study, we analyzed expression of KLK7 in 15 colon cancer cell lines and in 38 human colonic tumors. In many human colon cancer cells, KLK7 mRNA was observed, which leads to KLK7 protein expression and secretion. Furthermore, KLK7 was detected in human colon adenocarcinomas, but it was absent in normal epithelia. KLK7 overexpression in HT29 colon cancer cells upon stable transfection with a KLK7 expression plasmid resulted in increased cell proliferation. Moreover, subcutaneous inoculation of transfected cells into nude mice led to increased tumor growth that was associated with increased tumor cell proliferation as reflected by a positive Ki-67 staining. Our results demonstrate the aberrant expression of KLK7 in colon cancer cells and tissues and its involvement in cell proliferation in vitro and in vivo. Thus, KLK7 may represent a potential therapeutic target for human colon tumorigenesis.

21 June 2017 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
TDTiphaine Delaunay
Tiphaine Delaunay
LDLydia Deschamps
Lydia Deschamps
MHMeriem Haddada
Meriem Haddada
FWFrancine Walker
Francine Walker
ASAntoninus Soosaipillai
Antoninus Soosaipillai
DDDALILA DARMOUL
DALILA DARMOUL
Members of the tissue kallikrein‐related peptidase (KLK) family not only regulate several important physiological functions, but aberrant expression has also been associated with various malignancies. Clinically, KLKs have been suggested as promising biomarkers for diagnosis and prognosis in many types of cancer. As of yet, expression of KLKs and their role in skin cancers are, however, poorly addressed. Malignant melanoma is an aggressive disease associated with poor prognosis. Hence, diagnostic biomarkers to monitor melanoma progression are needed. Herein, we demonstrate that although mRNA of several KLKs are aberrantly expressed in melanoma cell lines, only the KLK7 protein is highly secreted in vitro. In line with these findings, ectopic expression of KLK7 in human melanomas and its absence in benign nevi were demonstrated by immunohistochemistry in vivo. Interestingly, overexpression of KLK7 induced a significant reduction in melanoma cell proliferation and colony formation. Moreover, KLK7 overexpression triggered an increase in cell motility and invasion associated with decreased expression of E‐cadherin and an upregulation of MCAM/CD146. Our results demonstrate, for the first time, that aberrant KLK7 expression leads to a switch from proliferative to invasive phenotype, suggesting a potential role of KLK7 in melanoma progression. Thus, we hypothesize that KLK7 may represent a potential biomarker for melanoma progression.

19 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
HBHayet Bouzid
Hayet Bouzid
FSFeryel SOUALMIA
Feryel SOUALMIA
KOKaterina Oikonomopoulou
Katerina Oikonomopoulou
ASAntoninus Soosaipillai
Antoninus Soosaipillai
FWFrancine Walker
Francine Walker
DDDALILA DARMOUL
DALILA DARMOUL
Kallikrein-related peptidases (KLKs) are implicated in many cancer-related processes. KLK6, one of the 15 KLK family members, is a promising biomarker for diagnosis of many cancers and has been associated with poor prognosis of colorectal cancer (CRC) patients. Herein, we evaluated the expression and cellular functions of KLK6 in colon cancer-derived cell lines and in clinical samples from CRC patients. We showed that, although many KLKs transcripts are upregulated in colon cancer-derived cell lines, KLK6, KLK10, and KLK11 are the most highly secreted proteins. KLK6 induced calcium flux in HT29 cells by activation and internalization of protease-activated receptor 2 (PAR2). Furthermore, KLK6 induced extracellular signal–regulated kinases 1 and 2 (ERK1/2) phosphorylation. KLK6 suppression in HCT-116 colon cancer cells decreased the colony formation, increased cell adhesion to extracellular matrix proteins, and reduced spheroid formation and compaction. Immunohistochemistry (IHC) analysis demonstrated ectopic expression of KLK6 in human colon adenocarcinomas but not in normal epithelia. Importantly, high levels of KLK6 protein were detected in the ascites of CRC patients with peritoneal metastasis, but not in benign ascites. These data indicate that KLK6 overexpression is associated with aggressive CRC, and may be applied to differentiate between benign and malignant ascites.